Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Carcinoma, Hepatocellular 18Neoplasms 13Neoplasm Metastasis 13Melanoma 13Esophageal Neoplasms 12Nasopharyngeal Carcinoma 10Head and Neck Neoplasms 9Esophageal Squamous Cell Carcinoma 9Colorectal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Recurrence 7Pancreatic Neoplasms 7Rectal Neoplasms 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3

Interventions

pembrolizumab 188Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5belzutifan 5Dexamethasone 5durvalumab 4Surgical Procedures, Operative 4Radiotherapy 4Nivolumab 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Parkinson Disease 4, Autosomal Dominant Lewy Body × Immune Checkpoint Inhibitors × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡